Medications to Manage Nausea on Zepbound (tirzepatide): First-Line and Beyond

Does the Zepbound label recommend a first-line anti-nausea drug?

The label addresses GI tolerability through the dosing schedule: the escalation steps are stated to reduce the risk of gastrointestinal adverse reactions [1]. Zepbound starts at 2.5 mg once weekly for 4 weeks [1]. The 2.5 mg dose is for initiation, not maintenance [1]. After 4 weeks the dose goes to 5 mg, then increases by 2.5 mg after at least 4 weeks on the current dose [1].

The label says to consider treatment response and tolerability when choosing maintenance, and to consider a lower maintenance dose if a dose is not tolerated [1]. For weight reduction, maintenance doses are 5, 10 or 15 mg weekly; for obstructive sleep apnea, they are 10 or 15 mg weekly [1]. The maximum is 15 mg weekly [1].

How common is nausea, and when does it happen?

In pooled Zepbound weight-reduction trials, nausea occurred in 8% of placebo patients and 25%, 29% and 28% of patients on 5, 10 and 15 mg [1]. Any gastrointestinal adverse reaction occurred in 56% on every Zepbound dose versus 30% on placebo [1]. Severe gastrointestinal reactions occurred in 1.7%, 2.5% and 3.1% versus 1% [1]. Treatment was discontinued for gastrointestinal reasons by 1.9%, 3.3% and 4.3% versus 0.5% [1]. The label says most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1].

What about ginger, vitamin B6, ondansetron and other antiemetics?

The Zepbound label does not mention ginger, vitamin B6, ondansetron or any other anti-nausea medicine. Its drug interaction section addresses delayed gastric emptying and oral medicines generally, saying to monitor oral medicines that depend on threshold concentrations or have a narrow therapeutic index, such as warfarin [1].

What label warnings matter when nausea is severe?

The label warns about acute kidney injury from volume depletion; the majority of reported events occurred in patients who had gastrointestinal reactions such as nausea, vomiting or diarrhea that led to dehydration [1]. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1]. Zepbound is not recommended in patients with severe gastroparesis [1]. If pancreatitis is suspected, the label says to discontinue Zepbound [1]. Persistent or severe abdominal pain, sometimes radiating to the back, may be a sign of pancreatitis and may or may not be accompanied by nausea or vomiting [1].